A total of 1247 patients with MDS, who were diagnosed between 1975 and 2002, were included in a joint database of the Austrian–German working group and examined in a retrospective manner. Of these ...
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk ...
The division of myelodysplastic syndromes (MDS) into low-risk and high-risk categories guides prognosis and treatment, with patients who have lower-risk disease typically receivin ...
The International Prognostic Scoring System (IPSS) was developed for adult MDS and includes weighted data on BM blast percentage, cytopenia, and cytogenetics, dividing patients into four prognostic ...
Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study Accurate determination of prognosis is critical for selection of ...
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data. An abstract and poster presented at the 2023 American ...
Myelodysplastic syndromes (MDS) are a diverse group of clonal stem cell disorders characterized by bone marrow failure, dysmyelopoiesis and peripheral cytopenias and affecting predominantly an elderly ...
Subgroup analyses showed consistently higher transfusion independence (TI) response rates than placebo across different risk groups regardless of International Prognostic Scoring System (IPSS), ...
The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients. Compared with patients ...
A new molecular scoring system promises to improve the treatment of a set of blood cancers called myelodysplastic syndromes (MDS), according to an international team of researchers. The findings were ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from its IMerge Phase 3 clinical trial ...
YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results